Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma
Epigenetic alterations have emerged as essential contributors in the pathogenesis of various human diseases, including cutaneous melanoma (CM). Unlike genetic changes, epigenetic modifications are highly dynamic and reversible and thus easy to regulate. Here, we present a comprehensive review of the...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/11/9/901 |
id |
doaj-c57f112123e34b1db0e743583203f7b7 |
---|---|
record_format |
Article |
spelling |
doaj-c57f112123e34b1db0e743583203f7b72021-09-26T00:32:07ZengMDPI AGJournal of Personalized Medicine2075-44262021-09-011190190110.3390/jpm11090901Interrogating Epigenome toward Personalized Approach in Cutaneous MelanomaElena-Georgiana Dobre0Carolina Constantin1Marieta Costache2Monica Neagu3Faculty of Biology, University of Bucharest, Splaiul Independentei 91–95, 050095 Bucharest, RomaniaImmunology Department, “Victor Babes” National Institute of Pathology, 050096 Bucharest, RomaniaFaculty of Biology, University of Bucharest, Splaiul Independentei 91–95, 050095 Bucharest, RomaniaFaculty of Biology, University of Bucharest, Splaiul Independentei 91–95, 050095 Bucharest, RomaniaEpigenetic alterations have emerged as essential contributors in the pathogenesis of various human diseases, including cutaneous melanoma (CM). Unlike genetic changes, epigenetic modifications are highly dynamic and reversible and thus easy to regulate. Here, we present a comprehensive review of the latest research findings on the role of genetic and epigenetic alterations in CM initiation and development. We believe that a better understanding of how aberrant DNA methylation and histone modifications, along with other molecular processes, affect the genesis and clinical behavior of CM can provide the clinical management of this disease a wide range of diagnostic and prognostic biomarkers, as well as potential therapeutic targets that can be used to prevent or abrogate drug resistance. We will also approach the modalities by which these epigenetic alterations can be used to customize the therapeutic algorithms in CM, the current status of epi-therapies, and the preliminary results of epigenetic and traditional combinatorial pharmacological approaches in this fatal disease.https://www.mdpi.com/2075-4426/11/9/901cutaneous melanomaepigenetic regulationinflammationdrug resistancebiomarkerstherapeutic targets |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elena-Georgiana Dobre Carolina Constantin Marieta Costache Monica Neagu |
spellingShingle |
Elena-Georgiana Dobre Carolina Constantin Marieta Costache Monica Neagu Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma Journal of Personalized Medicine cutaneous melanoma epigenetic regulation inflammation drug resistance biomarkers therapeutic targets |
author_facet |
Elena-Georgiana Dobre Carolina Constantin Marieta Costache Monica Neagu |
author_sort |
Elena-Georgiana Dobre |
title |
Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma |
title_short |
Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma |
title_full |
Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma |
title_fullStr |
Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma |
title_full_unstemmed |
Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma |
title_sort |
interrogating epigenome toward personalized approach in cutaneous melanoma |
publisher |
MDPI AG |
series |
Journal of Personalized Medicine |
issn |
2075-4426 |
publishDate |
2021-09-01 |
description |
Epigenetic alterations have emerged as essential contributors in the pathogenesis of various human diseases, including cutaneous melanoma (CM). Unlike genetic changes, epigenetic modifications are highly dynamic and reversible and thus easy to regulate. Here, we present a comprehensive review of the latest research findings on the role of genetic and epigenetic alterations in CM initiation and development. We believe that a better understanding of how aberrant DNA methylation and histone modifications, along with other molecular processes, affect the genesis and clinical behavior of CM can provide the clinical management of this disease a wide range of diagnostic and prognostic biomarkers, as well as potential therapeutic targets that can be used to prevent or abrogate drug resistance. We will also approach the modalities by which these epigenetic alterations can be used to customize the therapeutic algorithms in CM, the current status of epi-therapies, and the preliminary results of epigenetic and traditional combinatorial pharmacological approaches in this fatal disease. |
topic |
cutaneous melanoma epigenetic regulation inflammation drug resistance biomarkers therapeutic targets |
url |
https://www.mdpi.com/2075-4426/11/9/901 |
work_keys_str_mv |
AT elenageorgianadobre interrogatingepigenometowardpersonalizedapproachincutaneousmelanoma AT carolinaconstantin interrogatingepigenometowardpersonalizedapproachincutaneousmelanoma AT marietacostache interrogatingepigenometowardpersonalizedapproachincutaneousmelanoma AT monicaneagu interrogatingepigenometowardpersonalizedapproachincutaneousmelanoma |
_version_ |
1717365922157559808 |